Restoration Recovery is an outpatient addiction clinic with four locations across Southeast Tennessee and Northwest Georgia. We see patients weekly who are trying to read a rapidly changing kratom regulatory picture, both in the states we serve and in states where our patients’ families and referral sources are based. This article is factual reporting on U.S. kratom law as of April 2026; it is not legal advice. If you have a specific legal question about your state, consult an attorney licensed in that jurisdiction. What we can speak to clinically is how dependence on kratom or 7-OH is treated, and how that treatment picture is unaffected by what individual states are doing with their controlled-substance schedules.

The 2026 landscape — a regulatory patchwork

State kratom law in 2026 reflects a regulatory divide that has been widening for several years. Three distinct trajectories have emerged.

Full prohibition. Seven states treat kratom as a Schedule I or otherwise controlled substance, with possession, sale, and manufacture criminalized. Louisiana joined the banned-state list in August 2025; Connecticut followed on March 25, 2026. Tennessee, if Gov. Bill Lee signs HB1649/SB1656, becomes the eighth.

Kratom Consumer Protection Act regulation. More than thirty states regulate kratom under some version of the Kratom Consumer Protection Act framework, which keeps kratom legal for adults while imposing age, labeling, laboratory testing, and concentration-cap requirements. States in this category vary substantially in how strictly they enforce their KCPA rules.

The first reversal. Rhode Island, which banned kratom in 2017, reversed its ban effective April 1, 2026 — becoming the first state ever to move from full prohibition back to regulated-legal status. Advocacy groups argued that the ban pushed Rhode Island consumers to unregulated out-of-state and online sources without reducing dependence, and the state legislature accepted a KCPA-style framework as the replacement.

A fourth lane is not really a category but a status: active 2026 ban bills in Georgia, South Carolina, Washington, Michigan, Illinois, Kansas, West Virginia, Wyoming, and Maryland mean the list of banned states could grow meaningfully over the balance of the year. Whether those bills pass is uncertain; Tennessee’s April 2026 passage suggests that ban legislation has more momentum right now than it has had in several years.

Federal action on 7-hydroxymitragynine scheduling runs on a separate timeline. The FDA formally recommended to the DEA in July 2025 that concentrated 7-OH products be placed on Schedule I; the DEA is reviewing the recommendation through its standard rulemaking process. If the DEA acts, concentrated 7-OH becomes restricted nationwide regardless of what individual states do.

Fully banned: the seven states where kratom is illegal

As of April 2026, seven U.S. states treat kratom as a controlled substance or otherwise prohibited product. Possession, sale, and manufacture are criminal offenses; the specific penalties and statutory mechanisms vary by state.

Alabama — Schedule I since 2016

Alabama was the first state to classify mitragynine and 7-hydroxymitragynine as Schedule I controlled substances, under Alabama Code § 20-2-23. The ban has been in place since 2016. Knowing possession of any quantity is a Class C felony, and manufacture, delivery, or sale rises to a Class B felony. On March 25, 2026, the Alabama Attorney General issued a statewide cease-and-desist wave targeting retailers selling branded kratom and 7-OH products, including products sold under names like “Boujee Bliss,” “Better Weather,” and “Happy Hour.” For more detail, see our companion article on Alabama kratom law in 2026.

Arkansas — Schedule I since 2016

Arkansas followed Alabama’s lead in 2016, adding mitragynine and 7-hydroxymitragynine to the state’s Schedule I list. Penalties follow Arkansas’s general controlled-substance statute: possession is a felony, and trafficking carries multi-year prison exposure depending on quantity and prior record. Arkansas has not revisited its classification despite lobbying by kratom consumer groups in subsequent legislative sessions.

Indiana — banned under synthetic drug statute

Indiana’s approach differs from the Alabama/Arkansas Schedule I model. Rather than place kratom alkaloids on a controlled-substance list, Indiana classifies them under the state’s synthetic drug statute, which criminalizes possession, sale, and manufacture with penalty tiers comparable to controlled-substance offenses. The practical effect for consumers is the same: possession is a criminal offense, commercial retail is prohibited.

Louisiana — banned August 2025

Louisiana enacted a full kratom ban in August 2025, making it the sixth fully-banning state at the time. The Louisiana statute criminalizes possession, sale, and manufacture of kratom and its alkaloid derivatives. As with other banned-state regimes, post-effective-date enforcement has included retailer inspections and product-seizure authority for state officials; penalties escalate for repeat violations under the state controlled-substance statute.

Vermont — Schedule I

Vermont placed kratom on its Schedule I controlled-substance list several years ago. Possession and sale are criminal offenses. Vermont’s approach, like that of several other banned states, treats mitragynine and 7-hydroxymitragynine as a single regulated category rather than distinguishing between natural whole-leaf kratom and concentrated 7-OH products.

Wisconsin — Schedule I

Wisconsin treats kratom alkaloids as Schedule I controlled substances under state law. Possession and distribution are criminal offenses. Wisconsin has not adopted a KCPA-style regulatory alternative in subsequent legislative sessions despite proposals to reclassify or exempt specific product categories.

Connecticut — banned March 25, 2026 (newest)

Connecticut is the most recent addition to the banned-state list, with prohibition taking effect March 25, 2026. The Connecticut statute follows a Schedule I classification model, criminalizing possession, sale, and manufacture of kratom and its alkaloid derivatives. Retailers were given a compliance window to remove inventory before the effective date, and Connecticut state enforcement has ramped up product seizures since.

Rhode Island reversed its kratom ban — effective April 1, 2026

Rhode Island had banned kratom since 2017 under a Department of Health regulatory action that placed mitragynine and 7-hydroxymitragynine on the state’s prohibited-substance list. That ban was reversed effective April 1, 2026 — the first time any U.S. state has moved a controlled substance back to regulated-legal status after a prohibition. The new Rhode Island framework follows the Kratom Consumer Protection Act model: kratom is legal for adults aged 21 and older, subject to labeling requirements, third-party laboratory testing, limits on 7-OH concentration, and a prohibition on synthetic alkaloid additives.

The reversal argument that carried in Providence is one worth noting because it shapes the 2026-and-beyond debate in other states: advocates argued that a full ban pushed Rhode Island consumers toward unregulated out-of-state shipments and online vendors, increased exposure to adulterated and mislabeled products, and did not reduce kratom dependence or kratom-involved harm. The replacement KCPA framework kept kratom products inside a regulated retail channel where age, labeling, and testing rules are enforceable. Whether other banned states revisit their prohibitions in response to Rhode Island’s experience remains an open question. For now, Rhode Island is the single data point in that direction.

Regulated legal: the Kratom Consumer Protection Act framework

More than thirty U.S. states regulate kratom under some version of the Kratom Consumer Protection Act. The core of a KCPA-style framework is a shift from “unregulated supplement” treatment to “age-restricted, labeled, tested consumer product.” Key provisions typically include:

  • Minimum purchase age of 21. Retailers must verify age before sale; selling to minors carries escalating fines and potential license consequences.
  • Product labeling requirements. Every package must disclose mitragynine content, 7-hydroxymitragynine content, recommended serving size, batch or lot identifier, expiration date, and a visible 21-plus warning. Some states require additional disclosures such as habit-forming language and FDA-non-evaluation statements.
  • 7-OH concentration caps. Most KCPA states cap 7-hydroxymitragynine at 2 percent of total alkaloid content in any kratom product sold within state borders. Some set absolute-milligram caps in addition.
  • Prohibition on synthetic alkaloids. Manufacturers cannot chemically modify kratom alkaloids or spike products with synthesized mitragynine or 7-OH isolates.
  • Third-party laboratory testing. Products must be tested for alkaloid content, heavy metals (lead, arsenic, cadmium, mercury), pesticides, and microbial contaminants. Certificates of Analysis must be made available on request.
  • Processor-level registration in states with stricter frameworks. Some KCPA states, including Georgia under HB757, require kratom processors to register their products annually with state regulators and attest to FDA-facility manufacturing.

Representative KCPA-adopting states include Arizona, Colorado, Georgia, Kentucky, Maryland, Nebraska, Nevada, New York (2026), Oklahoma, Oregon, Rhode Island (as of April 1, 2026), South Dakota, Texas, Utah, and Virginia. Thirteen states have explicit labeling-rule requirements; about thirty have some form of regulation, though the strictness and enforcement posture vary widely. In practical terms, a kratom consumer in Arizona, Georgia, or Utah encounters products at retail that are age-verified, behind-counter, and labeled to a common standard; enforcement of violations is civil and retailer-focused rather than consumer-focused, meaning possession by a 21-plus adult is not a criminal matter.

Pending 2026 legislation — bills that could change the map

Several states have active 2026 legislation that would move them between categories. The list below reflects bills that had cleared at least one legislative chamber or formal committee action as of April 24, 2026.

Tennessee — HB1649/SB1656 (passed both chambers, awaiting signature)

Tennessee’s HB1649/SB1656, called “Matthew Davenport’s Law,” passed both chambers on April 16, 2026 with a Senate vote of 23-3. The bill is on Gov. Bill Lee’s desk and would take effect July 1, 2026 if signed. Penalties are Class A misdemeanor for knowing possession, Class C felony for manufacture, delivery, or sale, and Class B felony for sale to a minor. Tennessee would become the eighth fully-banning state. The introduced version of the bill (HB1647/SB1655) carried a harsher Class D/Class B/Class A felony structure; the passed substitute reduced possession from felony to misdemeanor before clearing the legislature. For the detailed breakdown, see our Tennessee kratom ban law article.

Georgia — HB968 (proposed Schedule I, repeals KCPA)

Georgia’s HB968 would reclassify mitragynine and 7-hydroxymitragynine as Schedule I controlled substances under Georgia law and repeal portions of the existing 2019 Kratom Consumer Protection Act framework (as amended by HB181 in 2024 and HB757 later). As of April 2026, HB968 has not cleared either chamber; whether it advances in the 2026 session is uncertain. For a detailed picture of where Georgia kratom law stands today and what HB968 would do, see our Georgia kratom law article.

South Carolina — H.4636, H.4641, H.4648

South Carolina passed a Kratom Consumer Protection Act in 2025. Three bills introduced in the 2026 session — H.4636, H.4641, and H.4648 — would repeal the 2025 KCPA and reclassify kratom alkaloids as controlled substances. The bills are in committee as of April 2026. South Carolina would become the fourth state since late 2025 to move from regulated-legal to banned if any of the three bills advances.

Washington — SB 6287 (regulate) and SB 6196 (95% tax)

Washington has two competing bills on different philosophies. SB 6287 would establish a Kratom Consumer Protection Act framework with age-21, labeling, and testing requirements, moving Washington formally into the regulated-legal category. SB 6196 would impose a 95 percent excise tax on kratom products, which industry observers note would be effectively prohibitive for retail sales. Both bills were active as of April 2026.

Michigan — House-passed ban, Senate pending

The Michigan House passed a kratom ban bill on March 18, 2026. The bill is pending Senate consideration and, if enacted, would move Michigan into the fully-banned category. Michigan’s approach follows a Schedule I model similar to the structure Alabama and Arkansas use.

Introduced in multiple states

Kratom ban bills were introduced in the 2026 legislative session in Illinois, Kansas, West Virginia, Wyoming, and Maryland. None had advanced to a floor vote as of April 24, 2026. State-level ban bills frequently recur session after session, so introduction alone does not predict passage, but the breadth of introductions reflects the national momentum toward tighter kratom regulation.

Federal status — kratom unscheduled, 7-OH scheduling pending

At the federal level, kratom itself remains unscheduled under the Controlled Substances Act. The DEA did not follow through on a proposed temporary scheduling of mitragynine and 7-hydroxymitragynine that was floated and then withdrawn in 2016. In January 22, 2025, the DEA formally designated both alkaloids as “Drugs of Concern” — an administrative label signaling potential for abuse without scheduling the substances outright.

The federal picture shifted meaningfully on July 29, 2025, when the FDA formally recommended to the DEA that concentrated 7-hydroxymitragynine products be scheduled as Schedule I under the Controlled Substances Act. The recommendation was narrow: it targeted concentrated 7-OH products specifically — tablets, gummies, drink mixes, and shots with elevated 7-OH concentrations — rather than natural whole-leaf kratom. The DEA is reviewing the recommendation through its standard rulemaking process, which requires a public-comment period before any final scheduling action. Federal scheduling decisions typically take months to years, and the DEA had not published a proposed rule for 7-OH as of April 2026.

If concentrated 7-OH is federally scheduled, it becomes illegal to manufacture, sell, or possess nationwide — regardless of any individual state’s position. Natural whole-leaf kratom would remain unscheduled unless separately addressed. Our companion explainer on 7-OH versus whole-leaf kratom covers the pharmacology and regulatory distinction in more depth, and our Is 7-OH banned yet? 2026 status tracker follows the federal scheduling timeline.

What any state’s status means for treatment access

This is the part of the article that matters most for anyone reading because they or someone they care about is dependent on kratom or 7-OH. The legal status of kratom in your state does not affect whether treatment is available, effective, or covered by insurance. It only affects supply.

Buprenorphine-based MAT works for kratom dependence regardless of state law

Kratom’s primary active alkaloids, mitragynine and 7-hydroxymitragynine, act on the same mu-opioid receptors that fentanyl, heroin, and prescription opioids act on. Although kratom is not itself a classical opioid, the receptor activity means that the same medication-assisted treatment protocol used for opioid use disorder is clinically effective for kratom dependence. Buprenorphine, the active medication in Suboxone, Sublocade, and Brixadi, is a partial opioid agonist that relieves kratom withdrawal, suppresses craving, and provides a stable transition off kratom products over weeks rather than days. These medications are legal and available in every U.S. state because they are FDA-approved with a federal indication for opioid use disorder.

Cross-state outpatient MAT if your home state has banned kratom

If you live in a state where kratom is banned and you are dependent, you can receive outpatient MAT in a neighboring state without any legal issue. Buprenorphine prescribing is governed by federal law and does not require residency in the prescribing state. Insurance coverage generally follows the patient rather than the provider location, with in-network status varying by carrier. In our own geography, Alabama residents from Jackson County routinely access Restoration Recovery’s Chattanooga clinic for outpatient MAT because kratom is banned in Alabama but legal and regulated in Tennessee. Patients in other regional patterns have similar options; the clinical and legal picture supports cross-border treatment access.

42 CFR Part 2 confidentiality regardless of state

Federal confidentiality protections under 42 CFR Part 2 apply to addiction treatment records regardless of the state in which care is delivered. This is a stricter standard than HIPAA and is explicitly designed to prevent disclosure of substance-use-disorder treatment to law enforcement, employers, or insurers without patient consent. Seeking treatment for kratom or 7-OH dependence does not generate a criminal record, a disclosure to kratom-law enforcement, or a public record that could affect employment, housing, or custody.

Common questions about kratom law by state

Which U.S. states have fully banned kratom as of April 2026?

Seven states have fully banned kratom as of April 2026: Alabama (Schedule I since 2016), Arkansas (Schedule I since 2016), Indiana (covered under synthetic drug statute), Louisiana (banned August 2025), Vermont (Schedule I), Wisconsin (Schedule I), and Connecticut (banned March 25, 2026). Tennessee would become the eighth if Gov. Bill Lee signs HB1649/SB1656, which passed both chambers on April 16, 2026. In banned states, possession, sale, and manufacture of kratom are criminal offenses with penalties ranging from misdemeanor (Tennessee’s pending bill) to felony (Alabama, Arkansas).

Is Rhode Island the first state to reverse a kratom ban?

Yes. Rhode Island had banned kratom since 2017 but reversed the ban effective April 1, 2026, making it the first U.S. state to reverse a prohibition. The new regulatory framework allows kratom sales to adults aged 21 and older with labeling, testing, and product-safety requirements modeled on the Kratom Consumer Protection Act used in other regulated states. The reversal was driven by advocacy arguments that a ban pushed consumers to unregulated sources and created patchwork enforcement problems without reducing dependence.

What is the Kratom Consumer Protection Act (KCPA)?

The Kratom Consumer Protection Act is a model regulatory framework that more than thirty U.S. states have adopted in some form. Core provisions typically include: a minimum purchase age of 21, mandatory product labeling with mitragynine and 7-hydroxymitragynine content, third-party laboratory testing for contaminants, caps on 7-OH concentration (commonly at 2 percent of total alkaloids), a prohibition on synthetic alkaloid additives, and penalties for retailers who sell to minors or mislabel products. States vary in how strictly they enforce KCPA provisions, what penalty structures they impose, and whether retail restrictions include behind-counter display requirements.

Which states have pending kratom ban bills in 2026?

Active 2026 kratom ban legislation includes Tennessee (HB1649/SB1656 passed both chambers April 16, 2026 and awaits Gov. Bill Lee’s signature; effective July 1, 2026 if signed), Georgia (HB968, which would repeal the 2019 Kratom Consumer Protection Act and classify mitragynine and 7-OH as Schedule I), South Carolina (H.4636, H.4641, H.4648 would repeal South Carolina’s 2025 KCPA and ban kratom), Washington (SB 6287 regulation approach and SB 6196 proposing a 95 percent excise tax), Michigan (House passed a ban March 18, 2026; Senate consideration pending), and introduced ban bills in Illinois, Kansas, West Virginia, Wyoming, and Maryland.

If I live in a banned-kratom state and am dependent, can I get treatment elsewhere?

Yes. Buprenorphine-based medication-assisted treatment (Suboxone, Sublocade, Brixadi) is legal in every U.S. state because it uses FDA-approved medications with a federal indication for opioid use disorder. Patients in banned-kratom states routinely cross state lines to receive outpatient MAT care in neighboring states. The legal status of kratom in your home state does not affect your ability to receive buprenorphine-based treatment or your insurance’s obligation to cover it. Restoration Recovery serves patients from across Tennessee, Georgia, and Alabama; other states have similar cross-border treatment access.

Where to check current state status

Kratom legislation can shift during a legislative session. For the most current state-level bill status, LegiScan and BillTrack50 publish up-to-date committee actions, floor votes, and signing actions for every state. State legislature websites (typically [state].gov or legis.[state].gov) publish full bill text and voting records. The American Kratom Association maintains a state-by-state status tracker and is a primary source for advocacy-side tracking of active bills. For the federal picture, DEA and FDA press releases and notices in the Federal Register are authoritative. We update this article and our Tennessee, Georgia, and Alabama state pages as bill status changes meaningfully.

This article is published for patient information only. It is not legal advice. If you have a specific legal question about your state or a potential cross-border scenario, consult an attorney licensed in the relevant jurisdiction.

If you are ready to stop using kratom or 7-OH

Whatever your state does with kratom legislation this year, the clinical reality is stable. Buprenorphine-based MAT works for kratom and 7-OH dependence, same-week appointments are available at our Chattanooga, Cleveland, Soddy-Daisy, and Ringgold locations, and most insurance plans cover treatment. Call 423-498-2000 or book a callback when you are ready. If you are outside our service area and looking for outpatient MAT, the same treatment protocols are available through any addiction clinic that prescribes buprenorphine.

Related reading